CN105452291B - 去除污染物的方法 - Google Patents

去除污染物的方法 Download PDF

Info

Publication number
CN105452291B
CN105452291B CN201480044463.6A CN201480044463A CN105452291B CN 105452291 B CN105452291 B CN 105452291B CN 201480044463 A CN201480044463 A CN 201480044463A CN 105452291 B CN105452291 B CN 105452291B
Authority
CN
China
Prior art keywords
apo
solution
virus
range
guhcl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201480044463.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN105452291A (zh
Inventor
G·瓦仁
Y·卢西亚
C·凯姆佩
M·斯图克基
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CSL Ltd
Original Assignee
CSL Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CSL Ltd filed Critical CSL Ltd
Priority to CN201910195678.2A priority Critical patent/CN109701004B/zh
Publication of CN105452291A publication Critical patent/CN105452291A/zh
Application granted granted Critical
Publication of CN105452291B publication Critical patent/CN105452291B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/34—Extraction; Separation; Purification by filtration, ultrafiltration or reverse osmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Water Supply & Treatment (AREA)
  • Analytical Chemistry (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
CN201480044463.6A 2013-08-08 2014-08-08 去除污染物的方法 Active CN105452291B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201910195678.2A CN109701004B (zh) 2013-08-08 2014-08-08 去除污染物的方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13179755.7 2013-08-08
EP13179755 2013-08-08
PCT/AU2014/000790 WO2015017888A1 (en) 2013-08-08 2014-08-08 Contaminant removal method

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201910195678.2A Division CN109701004B (zh) 2013-08-08 2014-08-08 去除污染物的方法

Publications (2)

Publication Number Publication Date
CN105452291A CN105452291A (zh) 2016-03-30
CN105452291B true CN105452291B (zh) 2019-03-19

Family

ID=48948309

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201480044463.6A Active CN105452291B (zh) 2013-08-08 2014-08-08 去除污染物的方法
CN201910195678.2A Active CN109701004B (zh) 2013-08-08 2014-08-08 去除污染物的方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201910195678.2A Active CN109701004B (zh) 2013-08-08 2014-08-08 去除污染物的方法

Country Status (13)

Country Link
US (3) US10087235B2 (cg-RX-API-DMAC7.html)
EP (2) EP3030578B1 (cg-RX-API-DMAC7.html)
JP (1) JP6530394B2 (cg-RX-API-DMAC7.html)
KR (1) KR102437202B1 (cg-RX-API-DMAC7.html)
CN (2) CN105452291B (cg-RX-API-DMAC7.html)
AU (1) AU2014305646C1 (cg-RX-API-DMAC7.html)
CA (1) CA2920391C (cg-RX-API-DMAC7.html)
DK (1) DK3030578T3 (cg-RX-API-DMAC7.html)
ES (1) ES2689333T3 (cg-RX-API-DMAC7.html)
HK (1) HK1225737B (cg-RX-API-DMAC7.html)
NZ (1) NZ631126A (cg-RX-API-DMAC7.html)
PL (1) PL3030578T3 (cg-RX-API-DMAC7.html)
WO (1) WO2015017888A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3030578B1 (en) * 2013-08-08 2018-07-04 CSL Limited Contaminant removal method
TW201941813A (zh) * 2018-02-19 2019-11-01 美商拜耳保健有限責任公司 改良的濾膜及方法
FR3090321B1 (fr) * 2018-12-21 2023-07-14 Lab Francais Du Fractionnement Procédé de filtration du fibrinogène
WO2020202831A1 (ja) * 2019-03-29 2020-10-08 国立研究開発法人量子科学技術研究開発機構 放射性医薬の製造方法及び放射性医薬
CN111351893A (zh) * 2020-04-28 2020-06-30 黄河三角洲京博化工研究院有限公司 一种利用离子色谱检测盐酸胍样品中胍离子含量的方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101778860A (zh) * 2007-08-17 2010-07-14 Csl百灵有限公司 α-1-抗胰蛋白酶和载脂蛋白A-I的纯化方法
CN103118683A (zh) * 2010-06-30 2013-05-22 Csl有限公司 重建高密度脂蛋白制剂及其生产方法
CN104017076A (zh) * 2014-01-06 2014-09-03 宁波博泰生物技术有限公司 载脂蛋白aⅰ抗血清的制备方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1335077C (en) 1988-02-08 1995-04-04 Henri Isliker Process for the manufacture of apolipoproteins from human blood plasma or serum
US5652339A (en) * 1993-12-31 1997-07-29 Rotkreuzstiftung Zentrallaboratorium Method of producing reconstituted lipoproteins
SE9500724D0 (sv) * 1994-06-23 1995-02-24 Pharmacia Ab Filtrering
SE9603068D0 (sv) * 1996-08-23 1996-08-23 Pharmacia & Upjohn Ab Process for purifying a protein
DE10211632A1 (de) 2002-03-15 2003-10-09 Aventis Behring Gmbh Verfahren zur Abtrennung von Viren aus einer Proteinlösung durch Nanofiltration
WO2003105989A1 (en) 2002-06-14 2003-12-24 Centocor, Inc. Use of a clathrate modifier to promote passage of proteins during nanofiltration
US20110178029A1 (en) * 2007-09-14 2011-07-21 Ambrx, Inc. Modified Human Apolipoprotein A-1 and Their Uses
WO2011044545A2 (en) * 2009-10-09 2011-04-14 Sigalov Alexander B Methods and compositions for targeted imaging
CN105288589A (zh) * 2011-02-07 2016-02-03 塞勒尼斯医疗控股公司 脂蛋白复合物及其制备和用途
US9125943B2 (en) 2012-11-02 2015-09-08 Csl Limited Reconstituted HDL formulation
NZ631116A (en) 2013-06-05 2018-07-27 Csl Ltd Process for preparing apolipoprotein a-i (apo a-i)
EP3030578B1 (en) * 2013-08-08 2018-07-04 CSL Limited Contaminant removal method

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101778860A (zh) * 2007-08-17 2010-07-14 Csl百灵有限公司 α-1-抗胰蛋白酶和载脂蛋白A-I的纯化方法
CN103118683A (zh) * 2010-06-30 2013-05-22 Csl有限公司 重建高密度脂蛋白制剂及其生产方法
CN104017076A (zh) * 2014-01-06 2014-09-03 宁波博泰生物技术有限公司 载脂蛋白aⅰ抗血清的制备方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
《Manufacturing and Shelf Stability of Reconstituted High-density Lipoprotein for Infusion Therapy》;Kim. J. et al;《BIOTECHNOLOGY AND BIOPROCESS ENGINEERING》;20110831;第16卷(第4期);摘要以及2.2节 *
《Virus inactivation of plasma-derived proteins by pasteurization in the presence of guanidine hydrochloride》;SCHLEGEL A. ET AL.;《TRANSFUSION》;20010301;第41卷(第3期);摘要以及表1，讨论部分 *

Also Published As

Publication number Publication date
DK3030578T3 (en) 2018-10-15
WO2015017888A8 (en) 2015-10-01
WO2015017888A1 (en) 2015-02-12
JP2016528233A (ja) 2016-09-15
EP3418290A1 (en) 2018-12-26
JP6530394B2 (ja) 2019-06-12
CA2920391C (en) 2023-03-28
EP3030578B1 (en) 2018-07-04
US20190119354A1 (en) 2019-04-25
EP3030578A1 (en) 2016-06-15
KR20160040299A (ko) 2016-04-12
US10730927B2 (en) 2020-08-04
US20160176947A1 (en) 2016-06-23
AU2014305646B2 (en) 2018-06-14
US10087235B2 (en) 2018-10-02
EP3030578A4 (en) 2017-04-26
CA2920391A1 (en) 2015-02-12
AU2014305646C1 (en) 2019-01-17
US11732028B2 (en) 2023-08-22
CN109701004B (zh) 2022-11-08
HK1225737B (en) 2017-09-15
CN109701004A (zh) 2019-05-03
KR102437202B1 (ko) 2022-08-29
AU2014305646A1 (en) 2016-02-18
NZ631126A (en) 2018-06-29
CN105452291A (zh) 2016-03-30
PL3030578T3 (pl) 2018-12-31
US20210147509A1 (en) 2021-05-20
ES2689333T3 (es) 2018-11-13

Similar Documents

Publication Publication Date Title
CN105452291B (zh) 去除污染物的方法
ES2718234T3 (es) Una formulación de lipoproteína de alta densidad reconstituida y método de producción de la misma
JPH07242699A (ja) 再構成リポタンパク質の製造方法
Lemieux et al. Importance of detergent and phospholipid in the crystallization of the human erythrocyte anion-exchanger membrane domain
US7879331B2 (en) Ultra-high yield intravenous immune globulin preparation
JP2021520233A (ja) Ａａｖ組成物、作製する方法及び使用の方法
HK1225737A1 (en) Contaminant removal method
CN107271698B (zh) 凝血酶原时间的测定方法、测定用试剂及其制造方法
US8293242B2 (en) Ultra-high yield of alpha-1-anti-trypsin
US7879332B2 (en) Ultra-high yield intravenous immune globulin preparation
ES2940304T3 (es) Proceso para preparar apolipoproteína A-I (Apo A-I)
René et al. Extracellular vesicles efficiently deliver survival motor neuron protein to cells in culture
Luo et al. Developing High-Yield and Safe Therapeutic EVs by Ablating Tissue Factor-Mediated Toxicity
Sanders et al. Similar structures of influenza M2 transmembrane domain in liposomes and in native E. coli membranes at physiological pH
Chau et al. Investigating spike S2 subunit hairpin proteins of the SARS-CoV-2 virus
KR20170008882A (ko) 암 치료용, 접합 치료 백신의 개발용, 및 접종제용으로 사용되는 생물학적으로 안전한 klh 제품의 신규 생성을 위한 제조 방법

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant